DNA Diagnostics Center Partners with Contraline in ADAMTM Clinical Trial, Testing Revolutionary Male Contraceptive
June 21 2024 - 7:13AM
Business Wire
DNA Diagnostics Center (DDC), a global leader in consumer
testing services, and part of the global network of Eurofins
laboratories, announces its collaboration with Contraline, a
clinical-stage medical device company specializing in reproductive
health innovation, in their first of a kind clinical trial for
ADAMTM, an investigational male contraceptive device.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240620661738/en/
DNA Diagnostics Center Partners with
Contraline in ADAMTM Clinical Trial, Testing Revolutionary Male
Contraceptive (Photo: DNA Diagnostics Center)
ADAMTM represents a significant advancement in male
contraception. It involves injecting a proprietary hydrogel into
the vas deferens, providing long-lasting and non-hormonal
contraception for male patients. ADAMTM occludes sperm transport
within the vas deferens, similar to a vasectomy, however, is
designed to be non-permanent and easier to reverse. This innovative
approach aims to offer men an alternative to traditional
contraceptive methods such as condoms and vasectomy. Contraline's
ADAMTM Study, a First-in-Human trial conducted in Australia, has
fully enrolled 25 patients into the study and is now focusing on
monitoring the long-term safety and efficacy of the device.
Contraline received approval from the Human Research Ethics
Committee (HREC) to integrate DDC’s SpermCheck Vasectomy® into the
ADAMTM Study protocol. SpermCheck Vasectomy® is an accurate and
convenient at-home test kit designed to confirm the success of
vasectomy procedures by detecting the presence of sperm in semen
samples. SpermCheck Vasectomy® is a leading male fertility brand in
the US, with over one million units sold, and is currently an
investigational device in Australia.
SpermCheck Vasectomy® will be utilized by patients implanted
with ADAMTM to monitor the effectiveness of the male contraceptive
in real-time. By offering a user-friendly and accessible solution
for monitoring sperm presence, SpermCheck Vasectomy® enhances the
convenience and reliability of ADAMTM as a male contraceptive
option.
Kevin Eisenfrats, co-founder & CEO of Contraline, remarked,
“We are excited to integrate SpermCheck Vasectomy® into the trial.
It’s a natural fit to combine an at-home diagnostic like SpermCheck
Vasectomy® with a male contraceptive like ADAMTM because it will
offer patients the ability to know whether ADAMTM is working from
the privacy of their own home. We are excited to be collaborating
with DNA Diagnostics Center to make this happen.”
Both DNA Diagnostics Center and Contraline are dedicated to
advancing the field of male contraception and improving
reproductive health outcomes for individuals worldwide.
About DNA Diagnostics Center DNA Diagnostics Center (DDC)
is a global leader in DNA and personal health testing. The company
provides comprehensive testing services for paternity and family
relationships, fertility, lifestyle, veterinary, and consumer
health through its family of 8+ brands worldwide. DNA Diagnostics
Center is part of the Eurofins network of companies. To learn more,
visit www.dnacenter.com.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 62,000 staff across a
network of more than 900 laboratories in over 1,000 companies in 62
countries, Eurofins offers a portfolio of over 200,000 analytical
methods. Eurofins Scientific S.E. shares are listed on Euronext
Paris Stock Exchange.
About Contraline Contraline, Inc. is a
venture-backed, clinical-stage, medical device company focused on
innovation in reproductive health. The company is developing
ADAMTM, the world’s first hydrogel designed to provide
long-lasting, non-hormonal, and reversible contraception for men.
The company was founded in 2015 by Kevin Eisenfrats and Dr. John
Herr, and is headquartered in Charlottesville, Virginia. To learn
more, visit www.contraline.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620661738/en/
For further information: Christy Kaupinen Vice President
of Marketing Christine.Kaupinen@dnacenter.com